[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fWWIv3OvlRRJllNc7AajbZtY4GxCl3K6nE59ixpbrULY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":56,"rows":63},"Shirley Ryan AbilityLab",[4],174,false,70,2,11049,7,156,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Stroke",52,{"name":18,"count":19},"Spinal Cord Injuries",24,{"name":21,"count":22},"Spinal Cord Injury",16,{"name":24,"count":25},"Amputation",13,{"name":27,"count":28},"Aphasia",8,{"name":30,"count":28},"Multiple Sclerosis",{"name":32,"count":33},"Cerebral Palsy",6,{"name":35,"count":33},"Healthy",[37,42,47,52],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06853015","Double Dose 4-AP on Functional Recovery After Spinal Cord Injury","2026-03","Dalfampridine",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06377085","Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy","2026-12","5-Azacytidine 10mg\u002Fm^2",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT07433023","tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy","2029-01-01","5-Azacitidine",{"nctId":53,"briefTitle":54,"date":55,"intervention":51},"NCT07434492","Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy","2030-08-31",[57,58,59,60,61,62],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[64,92,125,143,168,186,204,222,248,274,299,330,355,389,414,438,470,488,506,524,549,567,593],{"intervention":51,"totalTrials":9,"cells":65},{"EARLY_PHASE1":66,"PHASE1":69,"PHASE2":71,"PHASE3":86,"PHASE4":88,"NA":90},{"trials":67,"activeCount":68},[],0,{"trials":70,"activeCount":68},[],{"trials":72,"activeCount":9,"soonestReadout":50},[73,81],{"nctId":48,"briefTitle":49,"status":74,"phases":75,"primaryCompletion":50,"completion":50,"start":76,"enrollment":77,"conditions":78,"interventions":79},"RECRUITING",[59],"2026-05-28",80,[32],[51,80],"Mannitol",{"nctId":53,"briefTitle":54,"status":74,"phases":82,"primaryCompletion":55,"completion":55,"start":76,"enrollment":83,"conditions":84,"interventions":85},[59],60,[32],[51],{"trials":87,"activeCount":68},[],{"trials":89,"activeCount":68},[],{"trials":91,"activeCount":68},[],{"intervention":41,"totalTrials":9,"cells":93},{"EARLY_PHASE1":94,"PHASE1":107,"PHASE2":109,"PHASE3":119,"PHASE4":121,"NA":123},{"trials":95,"activeCount":68},[96],{"nctId":97,"briefTitle":98,"status":99,"phases":100,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":106},"NCT05447676","Effects of 4-AP on Functional SCI Recovery","UNKNOWN",[57],"2024-06-30","2025-06-30","2022-06-30",44,[21],[41],{"trials":108,"activeCount":68},[],{"trials":110,"activeCount":118,"soonestReadout":40},[111],{"nctId":38,"briefTitle":39,"status":74,"phases":112,"primaryCompletion":40,"completion":40,"start":113,"enrollment":114,"conditions":115,"interventions":117},[58,59],"2025-02-01",27,[116],"SCI - Spinal Cord Injury",[41],1,{"trials":120,"activeCount":68},[],{"trials":122,"activeCount":68},[],{"trials":124,"activeCount":68},[],{"intervention":80,"totalTrials":118,"cells":126},{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":137,"PHASE4":139,"NA":141},{"trials":128,"activeCount":68},[],{"trials":130,"activeCount":68},[],{"trials":132,"activeCount":118,"soonestReadout":50},[133],{"nctId":48,"briefTitle":49,"status":74,"phases":134,"primaryCompletion":50,"completion":50,"start":76,"enrollment":77,"conditions":135,"interventions":136},[59],[32],[51,80],{"trials":138,"activeCount":68},[],{"trials":140,"activeCount":68},[],{"trials":142,"activeCount":68},[],{"intervention":46,"totalTrials":118,"cells":144},{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":166},{"trials":146,"activeCount":68},[],{"trials":148,"activeCount":118,"soonestReadout":45},[149],{"nctId":43,"briefTitle":44,"status":150,"phases":151,"primaryCompletion":45,"completion":152,"start":153,"enrollment":114,"conditions":154,"interventions":156},"ENROLLING_BY_INVITATION",[58],"2027-07","2025-07",[32,155],"Contracture",[46,157,158,159],"5-Azacytidine 20mg\u002Fm^2","5-Azacytidine 35mg\u002Fm^2","5-Azacytidine 75mg\u002Fm^2",{"trials":161,"activeCount":68},[],{"trials":163,"activeCount":68},[],{"trials":165,"activeCount":68},[],{"trials":167,"activeCount":68},[],{"intervention":157,"totalTrials":118,"cells":169},{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":178,"PHASE3":180,"PHASE4":182,"NA":184},{"trials":171,"activeCount":68},[],{"trials":173,"activeCount":118,"soonestReadout":45},[174],{"nctId":43,"briefTitle":44,"status":150,"phases":175,"primaryCompletion":45,"completion":152,"start":153,"enrollment":114,"conditions":176,"interventions":177},[58],[32,155],[46,157,158,159],{"trials":179,"activeCount":68},[],{"trials":181,"activeCount":68},[],{"trials":183,"activeCount":68},[],{"trials":185,"activeCount":68},[],{"intervention":158,"totalTrials":118,"cells":187},{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":196,"PHASE3":198,"PHASE4":200,"NA":202},{"trials":189,"activeCount":68},[],{"trials":191,"activeCount":118,"soonestReadout":45},[192],{"nctId":43,"briefTitle":44,"status":150,"phases":193,"primaryCompletion":45,"completion":152,"start":153,"enrollment":114,"conditions":194,"interventions":195},[58],[32,155],[46,157,158,159],{"trials":197,"activeCount":68},[],{"trials":199,"activeCount":68},[],{"trials":201,"activeCount":68},[],{"trials":203,"activeCount":68},[],{"intervention":159,"totalTrials":118,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":220},{"trials":207,"activeCount":68},[],{"trials":209,"activeCount":118,"soonestReadout":45},[210],{"nctId":43,"briefTitle":44,"status":150,"phases":211,"primaryCompletion":45,"completion":152,"start":153,"enrollment":114,"conditions":212,"interventions":213},[58],[32,155],[46,157,158,159],{"trials":215,"activeCount":68},[],{"trials":217,"activeCount":68},[],{"trials":219,"activeCount":68},[],{"trials":221,"activeCount":68},[],{"intervention":223,"totalTrials":118,"cells":224},"D-Cycloserine",{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":231,"PHASE4":233,"NA":246},{"trials":226,"activeCount":68},[],{"trials":228,"activeCount":68},[],{"trials":230,"activeCount":68},[],{"trials":232,"activeCount":68},[],{"trials":234,"activeCount":68},[235],{"nctId":236,"briefTitle":237,"status":238,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":245},"NCT02635893","Lower Limb Function After Spinal Cord Injury","COMPLETED",[61],"2021-03-09","2021-04-11","2019-06-21",257,[21],[223],{"trials":247,"activeCount":68},[],{"intervention":249,"totalTrials":118,"cells":250},"Hydromorphone ER",{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":257,"PHASE4":259,"NA":272},{"trials":252,"activeCount":68},[],{"trials":254,"activeCount":68},[],{"trials":256,"activeCount":68},[],{"trials":258,"activeCount":68},[],{"trials":260,"activeCount":68},[261],{"nctId":262,"briefTitle":263,"status":238,"phases":264,"primaryCompletion":265,"completion":265,"start":266,"enrollment":267,"conditions":268,"interventions":270},"NCT01455519","True Functional Restoration and Analgesia in Non-Radicular Low Back Pain",[61],"2014-12","2011-10",51,[269],"Low Back Pain",[249,271],"Sugar pill",{"trials":273,"activeCount":68},[],{"intervention":275,"totalTrials":118,"cells":276},"Bupivacaine",{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":283,"PHASE4":285,"NA":297},{"trials":278,"activeCount":68},[],{"trials":280,"activeCount":68},[],{"trials":282,"activeCount":68},[],{"trials":284,"activeCount":68},[],{"trials":286,"activeCount":68},[287],{"nctId":288,"briefTitle":289,"status":238,"phases":290,"primaryCompletion":291,"completion":265,"start":292,"enrollment":22,"conditions":293,"interventions":296},"NCT01632709","Pathophysiology of Post Amputation Pain",[61],"2014-10","2012-05",[294,295],"Amputation Stumps","Neuroma",[275],{"trials":298,"activeCount":68},[],{"intervention":300,"totalTrials":118,"cells":301},"Gralise",{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":310,"NA":328},{"trials":303,"activeCount":68},[],{"trials":305,"activeCount":68},[],{"trials":307,"activeCount":68},[],{"trials":309,"activeCount":68},[],{"trials":311,"activeCount":68},[312],{"nctId":313,"briefTitle":314,"status":315,"phases":316,"primaryCompletion":317,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":327},"NCT01678911","Efficacy of Gralise® for Chronic Pelvic Pain","TERMINATED",[61],"2014-03","2014-06","2012-08",11,[322,323,324,325,326],"Irritable Bowel Syndrome","Ulcerative Colitis","Interstitial Cystitis","Prostatitis","Pelvic Pain",[300],{"trials":329,"activeCount":68},[],{"intervention":331,"totalTrials":118,"cells":332},"levodopa\u002Fcarbidopa",{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":339,"PHASE4":351,"NA":353},{"trials":334,"activeCount":68},[],{"trials":336,"activeCount":68},[],{"trials":338,"activeCount":68},[],{"trials":340,"activeCount":68},[341],{"nctId":342,"briefTitle":343,"status":238,"phases":344,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":350},"NCT01429077","Augmenting Language Therapy for Aphasia: Levodopa",[59,60],"2012-03","2007-10",36,[349,15],"Nonfluent Aphasia",[331],{"trials":352,"activeCount":68},[],{"trials":354,"activeCount":68},[],{"intervention":356,"totalTrials":9,"cells":357},"Lexapro",{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":387},{"trials":359,"activeCount":68},[],{"trials":361,"activeCount":68},[362,372],{"nctId":363,"briefTitle":364,"status":99,"phases":365,"primaryCompletion":366,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":371},"NCT01788969","Serotonergic Modulation of Motor Function in Subacute and Chronic SCI",[58],"2016-12","2019-12","2005-06",42,[21],[356],{"nctId":373,"briefTitle":374,"status":99,"phases":375,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":380},"NCT01753882","Monoaminergic Modulation of Motor Function in Subacute Incomplete Spinal Cord Injury (SCI)",[58],"2020-07","2012-02",88,[21],[356],{"trials":382,"activeCount":68},[],{"trials":384,"activeCount":68},[],{"trials":386,"activeCount":68},[],{"trials":388,"activeCount":68},[],{"intervention":390,"totalTrials":118,"cells":391},"SSRI",{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":406,"PHASE3":408,"PHASE4":410,"NA":412},{"trials":393,"activeCount":68},[],{"trials":395,"activeCount":68},[396],{"nctId":397,"briefTitle":398,"status":238,"phases":399,"primaryCompletion":400,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":405},"NCT01751854","Enhanced Motor Recovery Using Serotonergic Agents in Stroke",[58],"2012-01","2004-12",30,[404],"Patients With Chronic Stroke",[390],{"trials":407,"activeCount":68},[],{"trials":409,"activeCount":68},[],{"trials":411,"activeCount":68},[],{"trials":413,"activeCount":68},[],{"intervention":415,"totalTrials":118,"cells":416},"Upper extremity training\u002FArmeo Spring",{"EARLY_PHASE1":417,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":418,"activeCount":68},[419],{"nctId":420,"briefTitle":421,"status":238,"phases":422,"primaryCompletion":423,"completion":102,"start":424,"enrollment":425,"conditions":426,"interventions":427},"NCT03643770","Effect of a Novel Intervention Using Daily Intermittent Hypoxia and High Intensity Training on Upper Limb Function in Individuals With Spinal Cord Injury",[57],"2023-06-28","2018-11-16",58,[18],[415],{"trials":429,"activeCount":68},[],{"trials":431,"activeCount":68},[],{"trials":433,"activeCount":68},[],{"trials":435,"activeCount":68},[],{"trials":437,"activeCount":68},[],{"intervention":439,"totalTrials":9,"cells":440},"sugar pill",{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":447,"PHASE4":449,"NA":455},{"trials":442,"activeCount":68},[],{"trials":444,"activeCount":68},[],{"trials":446,"activeCount":68},[],{"trials":448,"activeCount":68},[],{"trials":450,"activeCount":68},[451],{"nctId":262,"briefTitle":263,"status":238,"phases":452,"primaryCompletion":265,"completion":265,"start":266,"enrollment":267,"conditions":453,"interventions":454},[61],[269],[249,271],{"trials":456,"activeCount":68},[457],{"nctId":458,"briefTitle":459,"status":99,"phases":460,"primaryCompletion":461,"start":462,"enrollment":463,"conditions":464,"interventions":466},"NCT02136823","Impact of Persistent Conductances on Motor Unit Firing in SCI",[62],"2015-05","2009-06",50,[465],"Chronic Spinal Cord Injury",[439,467,468,469],"Riluzole","Isradipine","Memantine",{"intervention":467,"totalTrials":118,"cells":471},{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":476,"PHASE3":478,"PHASE4":480,"NA":482},{"trials":473,"activeCount":68},[],{"trials":475,"activeCount":68},[],{"trials":477,"activeCount":68},[],{"trials":479,"activeCount":68},[],{"trials":481,"activeCount":68},[],{"trials":483,"activeCount":68},[484],{"nctId":458,"briefTitle":459,"status":99,"phases":485,"primaryCompletion":461,"start":462,"enrollment":463,"conditions":486,"interventions":487},[62],[465],[439,467,468,469],{"intervention":468,"totalTrials":118,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":496,"PHASE4":498,"NA":500},{"trials":491,"activeCount":68},[],{"trials":493,"activeCount":68},[],{"trials":495,"activeCount":68},[],{"trials":497,"activeCount":68},[],{"trials":499,"activeCount":68},[],{"trials":501,"activeCount":68},[502],{"nctId":458,"briefTitle":459,"status":99,"phases":503,"primaryCompletion":461,"start":462,"enrollment":463,"conditions":504,"interventions":505},[62],[465],[439,467,468,469],{"intervention":469,"totalTrials":118,"cells":507},{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":516,"NA":518},{"trials":509,"activeCount":68},[],{"trials":511,"activeCount":68},[],{"trials":513,"activeCount":68},[],{"trials":515,"activeCount":68},[],{"trials":517,"activeCount":68},[],{"trials":519,"activeCount":68},[520],{"nctId":458,"briefTitle":459,"status":99,"phases":521,"primaryCompletion":461,"start":462,"enrollment":463,"conditions":522,"interventions":523},[62],[465],[439,467,468,469],{"intervention":525,"totalTrials":118,"cells":526},"Lubiprostone",{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":535,"NA":537},{"trials":528,"activeCount":68},[],{"trials":530,"activeCount":68},[],{"trials":532,"activeCount":68},[],{"trials":534,"activeCount":68},[],{"trials":536,"activeCount":68},[],{"trials":538,"activeCount":68},[539],{"nctId":540,"briefTitle":541,"status":238,"phases":542,"primaryCompletion":266,"completion":266,"start":543,"enrollment":544,"conditions":545,"interventions":547},"NCT00662363","Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation",[62],"2008-04",64,[546],"Constipation",[525,548],"Senna",{"intervention":548,"totalTrials":118,"cells":550},{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":557,"PHASE4":559,"NA":561},{"trials":552,"activeCount":68},[],{"trials":554,"activeCount":68},[],{"trials":556,"activeCount":68},[],{"trials":558,"activeCount":68},[],{"trials":560,"activeCount":68},[],{"trials":562,"activeCount":68},[563],{"nctId":540,"briefTitle":541,"status":238,"phases":564,"primaryCompletion":266,"completion":266,"start":543,"enrollment":544,"conditions":565,"interventions":566},[62],[546],[525,548],{"intervention":568,"totalTrials":118,"cells":569},"Botulinum Toxin Type A - OnabotulinumtoxinA",{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":578,"NA":580},{"trials":571,"activeCount":68},[],{"trials":573,"activeCount":68},[],{"trials":575,"activeCount":68},[],{"trials":577,"activeCount":68},[],{"trials":579,"activeCount":68},[],{"trials":581,"activeCount":68},[582],{"nctId":583,"briefTitle":584,"status":238,"phases":585,"primaryCompletion":586,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":592},"NCT00661089","Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain and Spasticity",[62],"2009-03","2010-02","2003-09",21,[591],"Post-stroke Shoulder Pain and Spasticity",[568],{"intervention":594,"totalTrials":118,"cells":595},"Cyproheptadine",{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":602,"PHASE4":604,"NA":606},{"trials":597,"activeCount":68},[],{"trials":599,"activeCount":68},[],{"trials":601,"activeCount":68},[],{"trials":603,"activeCount":68},[],{"trials":605,"activeCount":68},[],{"trials":607,"activeCount":68},[608],{"nctId":609,"briefTitle":610,"status":238,"phases":611,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":619},"NCT02418949","Altering Activation Patterns Post-stroke",[62],"2019-08","2022-03-23","2015-11",96,[15,617,618],"Muscle Spasticity","Hemiparesis",[594]]